Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Items 401–500 of 509
GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists
Gillenwater, B. A., Wakefield, A. N., Triboletti, J. S., Gonzalvo, J. D., & Meredith, A. H. (2019) · AADE in Practice · doi:10.1177/2325160319861453 · Cited by 2
“Although rare, pancreatitis is a potential adverse effect of both classes, and it is unknown if the risk is increased when both agents are used together.(35,36) Data to demonstrate efficacy of this combination is lacking and adds additional expense without additional benefit.”
BackgroundPharmacological treatment of obesity
Ferreira‐Hermosillo, A., Salame, L., & Abruch, D. C. (2018) · PubMed · Cited by 10
Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective)
Goriacko, P., & Veltri, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-319-90761-1_10-1 · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
“The pancreatic and overall safety of incretin-based therapies, a commonly proposed second-line therapy, has increasingly been established even before the reassuring VERIFY results confirming lack of increased risk of pancreatitis in those with newly diagnosed disease [77,96-100].”
Freichel, M., & Mengel, K. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_11 · Cited by 8
Diabetes mellitus in the older adult
Caruso, L. B. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.030 · Cited by 2
[b]Actualisation[/b] 2015 du traitement de l’hyperglycémie dans le diabète de type 2
Scheen, A. J., & Paquot, N. (2015) · JMIG · doi:10.53738/revmed.2015.11.483.1518 · Cited by 3
Commentary: metformin use is associated with reduced gastric cancer risk
de Vries, A. C., & Kuipers, E. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12723 · Cited by 2
“Recently, use of incretins was reported to cause no increased risk of pancreatic cancer.(3) Metformin is generally considered the first-line drug for treating type 2 diabetes, and is one of the most commonly prescribed drugs worldwide.”
BackgroundDipeptidyl Peptidase 4 Inhibitors
Weber, A. E., & Thornberry, N. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc183.pub2 · Cited by 2
Yang, F. N., Zhao, Q., Dong, Y., Li, B., & Ning, B. (2022) · doi:10.37766/inplasy2022.3.0014 · Cited by 2
How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Inzucchi, S. E., & Matthews, D. R. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch33 · Cited by 2
AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES
Ismail, R., Anter, A. F., Matouk, A. I., & Heeba, G. H. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.160122.1493 · Cited by 2
Dipeptidyl Peptidase-4 – A Comprehensive Review
Parthasarathi, V., & Kanagarajan, H. (2025) · Current Enzyme Inhibition · doi:10.2174/0115734080377297250711143404 · Cited by 1
Inglot, T. W. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00646-9 · Cited by 1
Tassone, F., & Saraceno, G. (2025) · Biomedicines · doi:10.3390/biomedicines13102326 · Cited by 2
“Case reports and pharmacovigilance signals initially raised concerns of pancreatitis and pancreatic cancer [11].”
Pleiotropy of glucagon-like peptide-1 receptor agonists: too much of a good thing?
Scavalli, A. S., Biondi‐Zoccai, G., Bizzarri, F., & Frati, G. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.07174-1 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Klein, K. R., WYSHAM, C. H., Tuttle, K. R., Davies, M. J., Cox, D., Chen, J., Wu, W.-S., Denning, M., Liu, R., Ludwig, L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01865-9 · Cited by 3
Scheen, A. J. (2014) · RMLG. Revue médicale de Liège · Cited by 5
George, J. T. (2015) · Practical Diabetes · doi:10.1002/pdi.1976 · Cited by 1
Pancreatitis in incretin-based therapies
Famularo, G., Morviducci, L., & Gasbarrone, L. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.11.007 · Cited by 1
Halimi, S., & Lévy, M. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70804-1 · Cited by 2
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Araújo, L. M. D. M., Feguri, S., de Oliveira, T. L., Pedrosa, F. B., Guimarães, R. G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61007 · Cited by 2
“Many cases of pancreatitis have been reported in patients treated with exenatide, leading to the conduction informative and regulatory reviews [66].”
BackgroundChemoprävention – Was ist gesichert?
Kolligs, F. T., & Pox, C. P. (2017) · Der Onkologe · doi:10.1007/s00761-017-0207-9 · Cited by 1
Pancreatic Cancer Epidemiology and Environmental Risk Factors
Yellu, M., Kamireddy, C., & Olowokure, O. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_1 · Cited by 1
Gopinath, K., Nagarajan, S., & Muthusamy, K. (2018) · The Natural Products Journal · doi:10.2174/2210315508666180622113414 · Cited by 1
Anti-Diabetic Drugs & Cancer Risk Challenge
Anwar, E. I. (2019) · Diabetes & its Complications · doi:10.33425/2639-9326.1053 · Cited by 1
Freichel, M., & Mengel, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_14 · Cited by 1
Freichel, M., & Mengel, K. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_10 · Cited by 1
Freichel, M., & Mengel, K. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_15 · Cited by 1
Gysling, E. (2014) · pharma-kritik · doi:10.37667/pk.2014.925 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Linagliptin-Induced Pancreatitis
Sharu, H. E., Hidri, S., Peltz, J., & Alqaisieh, M. H. (2023) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.0316 · Cited by 1
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
Ganeva, M. G. (2023) · Trakia Journal of Sciences · doi:10.15547/tjs.2023.01.009 · Cited by 2
“Because of uncertainty regarding the association between the risk of acute pancreatitis and DPP-4 inhibitor use EMA and FDA state that pancreatic events will be considered a risk associated with DPP-4 inhibitors until more data are available (51).”
BackgroundAlghofaili, R., & Sekhar, C. (2025) · Cureus · doi:10.7759/cureus.86638 · Cited by 1
“This finding was supported by the European Medicines Agency and the Food and Drug Administration, which jointly conducted a comprehensive analysis of toxicology studies, revealing that they are less prone to pancreatitis following GLP-1 RA [29].”
Pitchumoni, C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_55 · Cited by 1
Diabetes therapy and cancer risk (October 2014)
Weiß, D. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81c.12001 · Cited by 1
Grimaldi, A., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30048-7 · Cited by 1
Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
Pratley, R. E. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0339 · Cited by 1
In Reply: Diabetes therapy and cancer risk (October 2014)
Sun, G. E. C., Kashyap, S. R., & Nasr, C. E. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81c.12002 · Cited by 1
CVD and type 2 diabetes: The nurse prescriber's role
Bostock-Cox, B. (2014) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2014.9.7.325
Cancers du pancréas et sécurité des incrétines : état des lieux en 2014
Halimi, S. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70835-1 · Cited by 1
Orale Antidiabetika ermöglichen eine individualisierte Therapie
Müller‐Wieland, D. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2719-9
Sitagliptin-Associated Pancreatitis: A Report of 4 Cases
Garin, A., Bouillou, F., Masson, E., Blétry, O., Penfornis, A., & Hammel, P. R. (2015) · International Journal of Case Reports in Medicine · doi:10.5171/2015.199809
New analyses of pancreatitis risk with incretin-based therapies
Weart, C. W. (2014) · Pharmacy Today · doi:10.1016/s1042-0991(15)30773-8
Detection of Genes Influencing Chronic and Mendelian Disease via Loss-Of-Function Variation
Li, A. H. (2015) · Digital Commons-TMC (Texas Medical Center)
Pampel, S. L. (2014) · Info Diabetologie · doi:10.1007/s15034-014-0604-8
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Hauner, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., Pfohl, M., Roden, M., et al. (2014)
Bessere Aussichten für Patienten mit Typ-2-Diabetes
Ritzel, R. A. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-7701-7
“Die Behörden (EMA, FDA) und Fachgesellscha¶en (EASD, ADA) schlussfolgerten, dass es keine Veränderung der Evidenz für eine adverse Wirkung von GLP-1-basierenden Substanzen auf das Pankreas gibt und dass keine hinreichende Evidenz für eine Änderung der gültigen ¡erapieempfehlungen vorliegt (bei akuter Pankreatitis in d…”
BackgroundDipeptidyl peptidase-4 inhibitors
Deacon, C. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_4
Preclinical Safety Assessment of Drug Candidate‐Induced Pancreatic Toxicity
Brenneman, K. A., Ramaiah, S. K., & Gauthier, L. M. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch17
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“evidence supporting this safety concern (296,297).”
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Diabetes arising from pancreatic exocrine problems
Morris, D. (2018) · Independent Nurse · doi:10.12968/indn.2018.10.21
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01185-0
Glucagonlike peptide 1 analogs in diabetes care.
Lindblad, A. J., Garrison, S., & Allan, G. M. (2017) · Europe PMC (PubMed Central)
Zhang, Q., Zhang, X., & Niu, C.-Y. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i11.393
Dipeptidyl Peptidase 4 Inhibitor, an Update
Lee, J. H. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.91
Jecht, M. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00829-6
“tung später von der US-amerikanischen „Food and Drug Administration“ und der europäischen Arzneimittelagentur zurückgewiesen wurde [18], könnten für PPDM besondere Überlegungen gelten, da Patienten mit akuter und chronischer Pankreatitis ein 2- bis 7-fach erhöhtes Pankreaskrebsrisiko haben [10, 11].”
BackgroundFreichel, M., & Mengel, K. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_13
Pitchumoni, C. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-90761-1_55-1
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Häring, H., Hauner, H., Joost, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., et al. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_4
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Freichel, M., & Mengel, K. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_14
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Freichel, M., & Mengel, K. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_12
Poewe, W. H., & Mahlknecht, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727879031.793537429
Incretin-based therapies linked to pancreatic cancer?
(2016) · Reactions Weekly · doi:10.1007/s40278-016-22586-x
FDA and EMA assess the pancreatic safety of incretin-based drugs
(2014) · Reactions Weekly · doi:10.1007/s40278-014-9307-0
Freichel, M., & Mengel, K. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_14
Alexanian, S. M., & Caruso, L. B. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.032
The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?
Taylor, J., Mpofu, R., & Blockman, M. (2022) · SA pharmaceutical journal. · doi:10.36303/sagp.2022.3.4.0137
Freichel, M., & Klinge, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_10
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Benyaminov, F., & Sinha, A. G. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_14
Freichel, M., & Klinge, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_10
Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss
Miller, A. (2024) · Journal of Aesthetic Nursing · doi:10.12968/joan.2024.13.1.6
Suleiman, М., Semenets, A. P., Kobzar, N., & Perekhoda, L. O. (2024) · Journal of organic and pharmaceutical chemistry · doi:10.24959/ophcj.24.302677
Noninsulin Diabetes Medications in Hospitalized Children and Adolescents
Vakharia, M. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.08.006
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
The Patient Evaluation and Optimization of Modifiable Risk Factors Before Revision THA
Novikov, D., Bartashevskyy, M., & Abdeen, A. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-83959-7_13 · Cited by 1
Miscellaneous drug combinations in diabetes mellitus
Agarwal, S., Devi, M., Mani, D. N., & Gupta, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00005-1
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
“Bei Pankreatitis konnte ebenfalls noch kein eindeutiger Zusammenhang mit der Therapie festgestellt werden [10], auch wenn Lipase-und Amylasewerte eindeutig erhöht sein können [11].”
Aktuelle Therapiekonzepte und Entwicklungen in der Diabetes mellitus Typ 2-Therapie
Honskamp, A. K. (2021) · Unipub UB Graz (Universität Graz)
Patients’ Experiences of Self-Care in Type 2 Diabetes Mellitus : A Qualitative Literature Review
Sonja Wahid Zadah, S., Nassolo, S., & Sayed, F. (2025) · Jonkoping University Library (Jönköping University)
Freichel, M., & Klinge, A. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_10
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Gill, H. (2025) · TSpace (University of Toronto)
Aung, K. Z., & Saw, N. (2026) · Cureus · doi:10.7759/cureus.111849
Can Semaglutide influence tumor biomarkers? Insight from a Clinical Case
Schianchi, A., Mauri, F., & Polli, C. (2026) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3594
“…cause pancreatic cancer, so regulatory agencies such as the FDA and EMA have reviewed the potential risks of pancreatic damage (tumoral or non-tumoral) associated with incretin peptides-based therapies, such as GLP-1RA, concluding that current data do not support a significant association [5].”
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.